U.K.’s Infirst Healthcare raises $30 million-plus to feed European OTC cough-cold and analgesic launches
LONDON — The U.K.’s Infirst Healthcare on Monday announced it has successfully raised $32.1 million in new funds. The funding, from Invesco Asset Management managed funds, will be used for the launch of the company’s medicines into the cough-cold and analgesic consumer healthcare markets.
Infirst will launch its first product, a cocoa-flavored cough liquid, in Europe. "Cough-cold and pain are the largest and most prevalent conditions in the consumer health sector and represent an enormous opportunity for Infirst to bring innovation and efficacy to a market which has seen very few new products and only marginal innovation for decades," stated Manfred Scheske, Infirst CEO.
The North American rights to Infirst’s cough-related launch have been out-licensed to Pernix Therapeutics Holdings.
Infirst is also developing an ibuprofen-based product for the treatment of inflammatory pain, to which it has the global rights, the company noted.
SanMedica unveils new HGH-booster at Academy of Women’s Health’s Annual Congress
WASHINGTON — SanMedica International on Friday introduced its SeroVital-HGH, a new oral human-growth hormone booster formulated with women in mind, at the Academy of Women’s Health’s Annual Congress here.
"Research is revealing that growth hormone is a vital aspect of women’s health that could affect everything from obesity to skin and aging to sex drive," stated Gina Daines, SanMedica spokeswoman. "Many of the women’s health experts attending this conference have seen that research and are beginning to realize the huge potential increased HGH levels could have for the women in their care."
"We’ve been thrilled about the opportunity to share our research with the highly respected group of women’s healthcare providers who are attending the conference," added Amy Heaton, SanMedica director of Scientific Affairs. "The research behind SeroVital is not only revolutionary because it proves there’s an oral compound capable of increasing growth hormone levels naturally — without synthetic injections — but also because it was the first clinical trial of its kind to test a compound’s growth hormone boosting effects not just on young males, but on both men and women across an appropriately wide age range. We think it’s important to let women’s health experts know just how well women responded to the SeroVital complex."
Bausch + Lomb files IPO registration with SEC
ROCHESTER, N.Y. — Bausch + Lomb on Friday announced that it has filed a registration statement with the U.S. Securities and Exchange Commission to take the company public. The number of shares to be offered and the price range for the proposed offering have not yet been determined, the company stated.
The proposed IPO could raise as much as $1.5 billion and is expected to value Bausch & Lomb at about $9 billion to $10 billion, Reuters reported earlier in March.
Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.